What this trial means for you
This study is recruiting now at 11 US sites. It's studying Cagrilintide, Placebo (matched to Cagrilintide) for obesity, overweight.
What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study, ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.
The study, in the sponsor's words
The purpose of this clinical study is to look at the safety of the medicine Cagrilintide when compared to placebo in people who do not tolerate marketed glucagon-like peptide-1 (GLP-1) therapies and who live with overweight or obesity. Participants will get either Cagrilintide (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participant will get is decided by chance. The study will last for about 8 months.
Can you join? The exact criteria
Below is the verbatim eligibility text from the registry. Bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.
Full eligibility criteria (for you and your doctor)
Key Inclusion Criteria: * Male or female (sex at birth) * Age 18 years or above at the time of signing the informed consent * History of documented treatment with GLP-1-RA medications with gastrointestinal (GI) adverse effects as the main reason for treatment discontinuation * Not suitable for re-initiation of GLP-1-RA treatment based on medical history and investigator judgement * Body mass index (BMI) greater than or equal to (≥) 30.0 kilograms per square meter (kg/m\^2) Key Exclusion Criteria: * Female who is pregnant, breast-feeding, or intends to become pregnant or is of childbearing potential and not using highly effective contraceptive methods * Treatment with GLP-1 receptor agonist or GLP-1-RA medication for any indication within 8 weeks before screening * History of type 1 or type 2 diabetes * Glycated haemoglobin (HbA1c) ≥ 6.5 percent (%) (48 millimole per mole \[mmol/mol\]) as measured by the central laboratory at screening * Treatment with glucose-lowering agent(s) prescribed for the indication of diabetes or pre-diabetes within 90 days before screening * Treatment with any medication prescribed for the indication of weight management within 8 weeks before screening
Study sites by state
California
- Diablo Clinical Research, Inc., Walnut Creek · Recruiting now
Florida
- Northeast Research Institute, Fleming Island · Recruiting now
- Jacksonville Ctr For Clin Res, Jacksonville · Recruiting now
- Center for Diab,Obes & Metab, Pembroke Pines · Recruiting now
- Encore Medical Research of Weston, Weston · Recruiting now
North Carolina
- Monroe Biomedical Research, LLC, Monroe · Recruiting now
- Accellacare, Wilmington · Recruiting now
South Carolina
- Coastal Carolina Research Ctr, North Charleston · Opening soon
Tennessee
- Holston Medical Group_Bristol, Bristol · Recruiting now
Texas
- Amarillo Medical Specialists, Amarillo · Recruiting now
- Elligo Clin Res Centre, Austin · Recruiting now
View the official record on ClinicalTrials.gov →
Follow this trial
Get an email when our monthly digest covers enrollment changes and results for trials like this one.